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ABSTRACT 
 In response to the growing rates of antibiotic resistance in human bacterial pathogens, 
this study explores the natural products involved in the defensive symbiosis between 
actinobacteria and fungus-growing ants to uncover new potential antibiotics. This study also 
seeks to understand the function of natural antibiotics in their ecological contexts, especially 
those involved in defensive symbioses. Defensive symbiosis can be a beneficial platform for 
discovering useful antibiotics, because antibiotics in these relationships must be able to 
selectively inhibit enemies without harming hosts, and are therefore likely more specific and 
less toxic. Pseudonocardia sp. associated with Trachymyrmex septentrionalis ants 
demonstrated antibiotic activity against several gram-positive bacteria. Therefore, the natural 
products from this strain were extracted and purified through activity-guided fractionation. 
Using mass spectrometry, the structure of the active compound was elucidated as 
GE37468A, an antibiotic that has been previously identified from Streptomyces sp. ATCC 
55365 from Italy. This compound had never before been characterized in a defensive 
symbiosis, which demonstrates the use of the molecule in a new context. Antibiotic 
GE37468A is a thiopeptide, which is a group of antibiotics that has previously demonstrated 
strong activity against many gram-positive bacteria, including bacterial human pathogens. 
Due to its potency against dangerous bacteria and its likely low toxicity, this antibiotic could 
therefore hold potential pharmacological uses.  
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INTRODUCTION 
Antibiotic resistance in human pathogens has been an ongoing challenge for the past 
several decades.1, 2 Since the 1960s, the pharmaceutical industry has struggled to keep up 
with the fast pace of resistance developing for each new antibiotic introduced in medicine.2 
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) pose the 
greatest risk to antibacterial resistance, as these bacteria are responsible for a breadth of 
serious infections and are also increasingly resistant to most antibacterial medications.3,4 
Methicillin-resistant Staphylococcus aureus (MRSA) has caused ongoing concern, as it is 
responsible for approximately 46,000 infections annually.5,6 For all common bacterial and 
fungal pathogens, resistance has been identified for most antibiotics developed and used in 
medicine.2,7,8  
The recent resurgence of antibiotic resistance has made the need for new antibiotics 
much more acute. The volume of novel antibiotics introduced by pharmaceutical companies 
has markedly reduced since the early 1980s.1, 2 In the search for novel antibiotics, natural 
products have served as a crucial starting point due to their breadth of chemical structures 
and wide range of antibiotic activities.9, 10 In fact, two of the most widely used antibiotics 
(penicillin and streptomycin) are both natural products, the former isolated from the fungus 
Penicillium notatum, and the latter from the bacteria Streptomyces griseus.11,12   The prospect 
of discovering novel natural products with high potency and low host toxicity is encouraging 
because several antibiotics have recently been identified against a variety of human 
pathogens, including teixobactin, ulleungamides A and B, copsin, and albicidin.13,14 
Commonly, organisms produce antibiotics as a form of defense. Many plant and 
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fungal species use natural products to protect themselves from predators or parasites. Other 
species use the antibiotics to defend their specialized niches from invasion by similar 
organisms.15 Researchers are currently exploring the use of natural products in defensive 
symbioses. In microbial defensive symbiosis, the microbe produces antibiotics to protect a 
host species from an enemy species; in return, the host promotes the fitness of the microbe, 
typically through nutrition-provision or protection from other enemies.16 The natural 
products from defensive symbiosis offer an underexplored context for natural product 
discovery, and are therefore a promising source for novel antibiotic development.  
This study specifically analyzes the natural products produced by actinobacteria that 
are involved in defensive symbiosis with a host organism: fungus-growing ants. Natural 
products from actinomycetes are one of the most promising sources of novel antibiotics 
because they are predicted to encode for a large diversity of antimicrobial drug classes that 
are yet to be explored.13, 14 Most antibiotics developed for pharmaceutical uses are 
actinomycete metabolites17 or chemical modifications of existing actinomycete products.15 
Considering previous successes in isolating novel antibiotics from bacteria involved in 
defensive symbiosis, this study focuses on actinobacteria of genus Pseudonocardia, which 
create antibiotics as part of a symbiotic relationship with fungus-growing ants. 
 
Fungus-Growing Ants 
 Fungus-farming ants have origins that trace back 45–65 million years. The ants, from 
the monophyletic tribe Attini, cultivate gardens of symbiotic fungi in their nests that serve as 
a primary food source for the ants.18 This cultivar fungus is transferred to new ant nests 
across generations.19 In return, the ants feed the cultivar with leaves, flowers, and vegetative 
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matter. There are over 200 described species of attine ants.18 Although found exclusively in 
the New World, fungus-farming ants are widely distributed across North, Central and South 
America, extending as far south as Chubut, Argentina and as far north as Long Island, New 
York.20 Common genera of fungus-farming ants include Acromyrmex, Apterostigma, Atta, 
Cyphomyrmex, and Trachymyrmex.17 
 While this mutualistic relationship between the ants and cultivar fungus has been 
established for several decades, recent studies have uncovered more complex relationships 
within this symbiosis. In studying the ant nests from several different species of attine ants, 
researchers observed the presence of a pathogenic fungus in addition to the cultivar.17 The 
pathogenic fungus, of genus Escovopsis, competes with the ants by consuming the cultivar 
fungus and overgrowing the fungal gardens.21 If allowed to grow freely, the Escovopsis will 
therefore eventually deplete the food source for the ant colony.22  
 To combat the presence of Escovopsis in fungal gardens, fungus-farming ants of 
several different genera were found to participate in a symbiotic relationship with specialized 
actinomycete bacteria. The actinomycetes live on the underside of the ants on an anatomical 
structure termed the propleural plates, resembling a white, powdery coating on the ant 
bodies.17 The ants secrete a nutrient-rich food source from specialized exocrine glands for the 
bacteria, and in exchange, the actinomycetes produce antifungal compounds that specifically 
target Escovopsis (Figure 1).17, 22 When new ant colonies are formed, the actinomycetes are 
transferred across generations such that all of the worker ants within a colony share the same 
strain of actinomycetes that have co-evolved with their ant hosts.23 Actinomycetes of genera 
Pseudonocardia, Streptomyces, and Amycolatopsis have been most commonly observed in 
this symbiotic relationship with ants.18  
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 In addition to the production of antifungal compounds, ant-associated 
Pseudonocardia have been found to produce antibacterial compounds as well. These 
antibacterial compounds allow the Pseudonocardia to defend its niche from invasion and 
occupation by other bacteria. Although the host bacterial strain is resistant to the produced 
antibiotic, these specialized antibacterial compounds target other closely related 
actinomycetes.19 
 
 
FIG 1. Overview of interactions between fungus farming ants, symbiotic cultivar fungus, symbiotic 
actinomycetes, and pathogenic Escovopsis fungus. Actinomycetes also produce antibacterial compounds to 
defend niche from other competitive actinomycetes. Green arrows represent a mutualistic interaction, whereas 
red bars indicate inhibition. Photos: Currie et al, 1999; Pagnocca et al., 2011; www.alexanderwild.com 
 
Studies of ant-associated have already identified a large variety of antifungal and 
antibacterial compounds. For example, Streptomyces strains isolated from Acromyrmex 
octospinosus ants in Panama were found to produce candicidins that can inhibit the human 
pathogenic fungus, Candida albicans.24, 25 Similarly, antifungal actinomycins D, X2, and 
X0Ββ were purified from Streptomyces associated with Acromyrmex echinator ants.26 From 
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Pseudonocardia associated with Apterostigma dentigerum ants in Panama, two antifungal 
compounds have been identified: dentigerumycin27 and selvamicin.28 Antibacterial 
compounds isolated from ant-associated bacteria include 9-methoxyrebeccamycin from 
Apterostigma dentigerum-associated Pseudonocardia,29 as well as elaiophylin, efomycin A 
and efomycin G produced by Streptomyces associated with Acromyrmex echinator.26  
 
Trachymyrmex septentrionalis 
 In this study, the natural products of bacterial strains associated with Trachymyrmex 
septentrionalis ants from Long Island, NY were investigated to identify associated 
antibiotics.  Trachymyrmex are higher attine ants that use dead vegetative matter to feed 
cultivar fungi.18 Trachymyrmex is the most abundant attine genera in the United States. 
Trachymyrmex nests are also found in a large variety of climates, ranging from tropical 
Central and South America to the temperate zones of the American Southwest and the cold 
environments of Long Island, NY.30  
Trachymyrmex septentrionalis nests are usually found in oak- or pine-dominated 
habitats with very sandy soils.30 Trachymyrmex ants typically store cultivar in nests 
consisting of multiple chambers that range from 0.5 to 4 meters deep.31 Although Escovopsis 
has never been isolated from the fungal gardens of North American Trachymyrmex ants,32, 33 
Trachymyrmex nests contain a large diversity of other fungal genera, including 
Cunninghamella, Fusarium, Mortierella, Penicillium, and Trichoderma.32 It is therefore 
believed that Trachymyrmex-associated actinomycetes may have some other specialized roles 
in the ant-cultivar symbiosis.33 According to one study, Pseudonocardia were the most 
prevalent actinomycetes found on Trachymyrmex ants.33 Prior studies of actinomycetes from 
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Trachymyrmex in Brazil identified two antifungal analogs that were both active against 
Candida albicans: urauchimycin A and urauchimycin B.34  
Considering prior successes in isolating antibiotics from ant-associated bacteria, the 
minimally studied Trachymyrmex actinobacteria hold promise as a source for a wide range of 
novel antibacterial and antifungal compounds. Furthermore, from an ecological context, 
studying the chemicals involved in the defensive symbiosis between Pseudonocardia and 
Trachymyrmex ants can help gain a better understanding how the two species interact with 
each other. Therefore, in this exploratory study, Trachymyrmex septentrionalis ants were 
collected from Long Island, NY, and Pseudonocardia were isolated from the propleural 
plates of the ants, and natural products were isolated from the bacteria. The active compound 
was then purified through activity-guided fractionation, and the structure of the antibiotic 
compound was elucidated through mass spectrometry techniques.  
METHODS 
Initial “Resident-Intruder” Assay with Bacterial Intruders 
Pseudonocardia strains EV170527-10 (17SE-10), EV170527-11 (17SE-11), 
EV170708-06 (17SM-6), EV170708-14 (17SM-14), and EV170708-15 (17SM-15) were 
collected and cultured by Dr. Ethan Van Arnam from Trachymyrmex septentrionalis (17SE-
10 and 17SE-11) ants from Long Island, NY and Trachymyrmex smithi (17SM-6, 17SM-14, 
and 17SM-15) ants from Las Cruces, NM. Spores were cultured, collected, and stored in a 
25% glycerol solution at –20 °C. The concentrated spore suspension of each of these 
“resident” Pseudonocardia strains (5 µL) was spotted to the center of a 60 x 15 mm Petri 
dish with 8 mL yeast malt extract agar (YMEA, 1.5% agar). Three “resident” plates were 
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prepared per strain of Pseudonocardia. One of these plates per strain had no intruders plated 
(positive control). These plates were incubated for 14 days at 30 °C.  
Concentrated spore suspensions of “intruder” strains of Pseudonocardia (5 µL) were 
spread around the center colony from the plates above and around the remainder of the plate 
surface area with a wetted sterile cotton swab, using 200 µL of sterile water per plate to assist 
in spreading. Intruder strains used included EC080529-05 (PLR-2) and EV170708-01 
(17SM-1). As a negative control, intruders were also spread evenly across plates with no 
resident colonies. These plates were incubated at 30 °C for an additional 7 days. Zones of 
inhibition were measured as the difference between the diameter of inhibition and the 
diameter of resident colony growth (Figure 2). 
To test 17SE-10 against even more intruders, a concentrated spore suspension of 
17SE-10 (5 µL) was spotted to the center of each of 10 Petri dishes (60 x 15 mm) filled with 
YMEA 1.5% media (8 mL). These plates were incubated for 14 days at 30 °C. 
Concentrated spore suspensions of “intruder” strains of Pseudonocardia (5 µL) were spread 
around the remainder of the plate with a wetted sterile cotton swab, using 200 µL of sterile 
water per plate to assist in spreading. Intruder strains tested included PLR-2, EV170527-09 
(17SE-9), and EV170527-03 (17SE-3). Two replicates were performed for each resident and 
intruder pair. Intruders were also spread evenly across plates with no resident colonies 
(negative control). Two of these plates had no intruders plated, and only sterile water was 
spread instead (negative control). All cultures were incubated at 30 °C for an additional 7 
days. Zones of inhibition were measured as the distance from the center of the resident 
colony to the closest edge of fungal growth (Figure 2). 
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FIG 2. Diagram of Resident-Intruder assays for bacterial (A) and fungal (B) intruders. To bacterial 
intruders, the zone of inhibition was measured as the difference between the diameter of the zone and 
the diameter of the resident colony. For the Escovopsis fungal intruder, the zone of inhibition was 
measured as the distance from the center of the resident colony to the closest edge of fungal growth. 
 
 
Initial “Resident-Intruder” Activity Assay with Fungal Intruders 
Concentrated spore suspension of each 17SE-10, 17SE-11, 17SM-6, 17SM-14, and 
17SM-15 (5 µL) was spotted 1 cm away from the edge of a 60 x 15 mm Petri dish filled with 
YMEA (1.5% agar) (8 mL). Two of these “resident” plates were prepared per 
Pseudonocardia strain tested. One of these plates per strain had no intruders plated (positive 
control). These plates were incubated for 14 days at 30 °C.  
 Escovopsis sp. (EV151027-02-2) was passaged onto a Petri dish filled with YMEA 
(2% agar) (25 mL). This plate was sealed with parafilm to maintain humidity and incubated 
at room temperature for 7 days. After incubation, a punch tool was used to punch holes into 
the agar of the plate along the periphery of the fungal growth. Then, one plug of fungus was 
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placed on each of the “resident” plates, directly across the plate from the resident-colony and 
1 cm away from the edge of the plate. These plates were sealed with parafilm to maintain 
humidity, and incubated at room temperature for 7 days. Zones of inhibition were measured 
as the distance from the center of the resident colony to the closest edge of fungal growth 
(Figure 2). 
 
Initial Spot-on-Lawn Activity Testing of Pseudonocardia Extracts 
A concentrated spore suspension of each 17SE-10, 17SE-11, 17SM-6, 17SM-14, and 
17SM-15 (5 µL) was spread evenly across a Petri dish (100 x 15 mm) filled with YMEA (2% 
agar) (25 mL), using 200 µL of sterile water per plate to assist with spreading. These plates 
were incubated at 30 ºC for 14 days.  
Agar from each plate was cut into 1cm x 1cm squares. The squares from each plate 
were then divided between two 50-mL centrifuge tubes. For each strain, 25 mL of ethyl 
acetate was added to one tube, and 25 mL of methanol was added to the other. Cultures were 
soaked in solvent for 24 hours, then decanted and fully evaporated. Each extract was 
subsequently rehydrated in 500 µL of methanol. 
Liquid cultures were prepared of each Bacillus subtilis and Escherichia coli. Luria 
broth (LB) media were added (4 mL) to each of two 13-mL snap-top culture tubes. Each 
were inoculated with a single colony of bacteria. Liquid cultures were incubated at 30 ºC and 
250 RPM on a shaking incubator for 24 hours. For each of strain of bacteria, 50 µL of liquid 
culture was combined with molten low-density LB (0.75 % agar) (4 mL) and quickly poured 
over a Petri dish (100 x 15 mm) filled with LB (2% agar) (25 mL). Simultaneously, 
concentrated spore suspension of PLR-2 (5 µL) was combined with molten low density 
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YMEA (0.75% agar) (4 mL) and quickly poured over a Petri dish with YMEA (2% agar) (25 
mL). Each extract was spotted onto the different plates (5 µL), spaced at approximately 2-cm 
intervals. An extract of EV151025-09-1 (GA6-1) was used as a positive control, and pure 
methanol was used as a negative control. All spotted plates were incubated at 30 ºC for 72 
hours. The diameter of each zone of inhibition was then measured. 
 
Culturing and Creation of Crude Extract 
Concentrated spore stock of 17SE-10 (20 µL) was spread evenly on each of 10 Petri 
dishes (150 x 15 mm) with YMEA 2% media (60 mL), using 200 µL of sterile water per 
plate to assist with spreading. These plates were incubated for 14 days at 30 °C. Agar was 
then cut into 1cm x 1cm squares and combined with 350 mL of ethyl acetate. Cultures were 
soaked in solvent for 24 hours, then decanted and fully evaporated. The dry extract was 
massed and rehydrated in 10 mL of methanol. 
 
Fractionation Through Reverse-Phase Column Chromatography 
CeliteⓇ powder was added to the methanol solution of crude extract in a three-fold 
greater proportion by mass than the dry extract and dried with a rotary evaporator. A 5 g C18 
SepPakⓇ column was attached to a vacuum manifold and preconditioned with water followed 
by 100% acetonitrile + 0.1% formic acid, followed by 20% acetonitrile and 0.1% formic acid 
in water. The CeliteⓇ + extract mixture was transferred to the top of the column using 
approximately 3 mL of a 20% acetonitrile + 0.1% formic acid solution. 10 fractions were 
eluted by running 10 mL of each of the following solvents 2 times each through the column: 
20%, 40%, 60%, 80%, and 100% acetonitrile + 0.1% formic acid in water. Fractions were 
evaporated and rehydrated in methanol (500 µL).  
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Spot-on-Lawn Activity Testing of Fractions 
A soft lawn of Pseudonocardia on agar was prepared by combining 4 mL molten 
low-density yeast malt extract agar (YMEA, 0.75 % agar) with PLR-2 spore stock (5 µL). 
This mixture was quickly and evenly poured over petri dishes (100 x 15 mm) filled with 
YMEA (2% agar) (25 mL). Fractions were spotted (5 µL) on top of the lawn along with the 
unfractionated extract (positive control) and methanol (negative control). The plates were 
incubated for 72 hours at 30 °C. The diameter of each zone of inhibition was then measured. 
 
Preparative Fractionation with Reverse-Phase HPLC 
 The fraction from SepPak chromatography that was most active against the 
Pseudonocardia strain PLR-2 (fraction 6) was further fractionated by preparative reverse-
phase high performance liquid chromatography (Column: KinetexⓇ 5 µm EVO C18 100 Å LC 
Column 250 x 10.0 mm) using a gradient concentration of acetonitrile + 0.1% formic acid in 
water from 30% to 100% over 20 minutes (flow rate: 2.500 mL/min, injection volume: 50 
µL) to elute. Fractions were collected in one-minute intervals. UV/Vis absorbances were 
measured across the full spectrum of wavelengths. Preparative fractionation was performed 
with four different injections, and corresponding fractions from each injection were pooled 
together. Fractions were then evaporated and rehydrated in methanol (200 µL). Activity of 
fractions was assessed through spot-on-lawn testing against PLR-2. The active fraction from 
the initial separation by SepPak chromatography was used as a positive control in activity 
testing. 
 
High-Resolution Mass Spectrometry and Initial Identification 
The active fraction purified through one round of reverse-phase HPLC fractionation 
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was sent to University of Illinois, Urbana-Champaign for high-resolution liquid-
chromatography mass spectrometry analysis (Waters Synapt G2-Si ESI MS, solvent: 10-
100% acetonitrile in water, collected over 10 min). High-resolution ESI-TOF mass 
spectrometry data was collected in both positive and negative ion modes. The active 
compound eluted at 4.798 minutes． 
 
Extraction and Fractionation of Streptomyces sp. ATCC 55365 
Streptomyces sp. strain ATCC 55365 (Streptomyces sp. Waksman and Henrici 
ATCC® 55365™) was purchased as a lyophilized solid. The solid was rehydrated in YMEA 
liquid media (1.000 mL). This culture was streaked across a 100 x 15 mm petri dish filled 
with (YMEA 2% agar) (25 mL) to isolate individual colonies, and incubated for 14 days at 
30ºC. A vial with 1000 µL of sterile water was inoculated with a single colony of 
Streptomyces. The spores were suspended, and evenly spread (200 µL) across each of 5 Petri 
dishes (150 x 15 mm) filled with YMEA (2% agar) (60 mL). These plates were incubated at 
30 ºC for 14 days. Agar from all plates was then cut into 1cm x 1cm squares and combined 
with 200 mL of ethyl acetate total. Cultures were soaked in solvent for 24 hours, and the 
solvent was decanted and fully evaporated to produce a dry extract that was then massed and 
rehydrated in methanol (10 mL). CeliteⓇ powder was added to the methanol solution of crude 
extract in a three-fold greater proportion by mass than the dry extract. The crude extract was 
separated into 10 fractions using reverse-phase SepPak column chromatography using the 
same procedure as above. Fractions were then assessed for activity using the spot-on-lawn 
assay.  
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HR-LCMS/MS Comparison of Streptomyces and 17SE-10 Active Compounds 
 Because the eighth fraction to elute from reverse-phase column chromatography of 
the Streptomyces sp. extract appeared to contain the most pure antibiotic through UV/Vis 
spectrometric analysis at 300 nm, this fraction was used for high resolution-liquid 
chromatography tandem mass spectrometry (HR-LCMS/MS) analysis and compared against 
a fraction of the 17SE-10 extract purified through preparative HPLC. A small volume (200 
µL) of each active fraction was dried with a rotary evaporator and sent to University of 
Illinois, Urbana-Champaign for analysis (Waters Synapt G2-Si ESI MS, solvent: 10-100% 
acetonitrile in water, collected over 10 min, CE = 28-33). Elutions were also analyzed for 
UV/Vis absorbance at 305 nm.  
RESULTS 
Initial “Resident-Intruder” Assay 
 “Resident-intruder” assays were completed to assess the antibiotic abilities of various 
Pseudonocardia symbionts isolated from Trachymyrmex ants. 17SE-10 and 17SE-11 were 
isolated from Trachymyrmex septentrionalis, and 17SM-6, 17SM-14, and 17SM-15 were 
isolated from Trachymyrmex smithi. All strains were tested for antibiotic activity against two 
bacterial strains (PLR-2 and 17SM-1), as well as the fungus Escovopsis. For 17SE-11 and 
17SM-14, zones of inhibition were irregular and non-uniform against 17SM-1. However, the 
inside of the inhibition zones also contained a clear, shiny film often associated with bacterial 
contamination and thus these zones could not be measured. Of all strains assessed, only 
17SE-10 demonstrated antibacterial activity, and activity against PLR-2 was almost twice the 
activity against 17SM-1. All strains demonstrated antifungal activity with respect to the 
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negative control. Antifungal activity was strongest for 17SM-6 and 17SM-15. The antifungal 
abilities for 17SE-10, 17SE-11, and 17SM-14 were all moderate and similar. Only 17SE-10 
showed activity against both fungi and bacteria (Table 1).  
 
TAB 1. Size of zone of inhibition (centimeters) for activity testing of various Pseudonocardia strains 
against three different intruders. 17SM-1 and PLR-2 are Pseudonocardia and Escovopsis is a type of 
fungus. The negative control condition only contained intruders (no residents were plated). Blank 
fields indicate no collected data due to contamination. 
 
 
 
Initial Spot-on-Lawn Activity Testing of Pseudonocardia Extracts 
 Extracts of 17SE-10, 17SE-11, 17SM-6, 17SM-14, and 17SM-15 were prepared using 
ethyl acetate and methanol as the extracting solvents. All extracts were all then evaporated 
and rehydrated in methanol to use for activity testing. Antibacterial activity against two 
different gram-positive bacterial strains (B. subtilis and Pseudonocardia-PLR-2) was 
assessed as well as one gram-negative strain (E. coli). Methanol and ethyl acetate extracts of 
Pseudonocardia strain GA6-1 were used as positive controls. This strain had been previously 
demonstrated to have strong antibiotic activity against gram-positive bacteria.  
 The positive control was an extract from a Pseudonocardia strain that had been 
known to produce antibiotics against gram-positive bacteria. This control created zones of 
inhibition against the PLR-2 and the B. subtilis, as expected. The negative control, methanol, 
  Intruder Strain 
Resident Strain 17SM-1 PLR-2 Escovopsis sp. 
17SE-10 1.20 2.10 2.45 
17SE-11 -- 0.00 2.25 
17SM-6 0.00 0.00 3.45 
17SM-14 -- 0.00 2.30 
17SM-15 0.00 0.00 3.25 
Neg. Control 0.00 0.00 1.30 
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did not demonstrate any inhibition. 
 
 
FIG 3. Initial spot-on-lawn activity testing of extracts of all strains against B. subtilis (A), 
Pseudonocardia PLR-2 (B), and E. coli (C). Strains were extracted in each ethyl acetate and 
methanol. Spots on each plate: 1: 17SE-10 in ethyl acetate, 2: 17SE-11 in ethyl acetate, 3: 17SM-15 
in ethyl acetate, 4: 17SM-6 in ethyl acetate, 5: 17SM-14 in ethyl acetate, 6: 17SE-10 in methanol, 7: 
17SE-11 in methanol, 8: 17SM-15 in methanol, 9: 17SM-6 in methanol, 10: 17SM-14 in methanol.  
 
None of the extracts demonstrated inhibition against E. coli. Extracts had similar 
activity against PLR-2 versus B. subtilis (Figure 3). The 17SE-10 extract prepared with ethyl 
acetate had the strongest inhibition against both strains of bacteria compared with other 
extracts (1.25 cm for PLR-2, 1.35 cm for B. subtilis). 17SE-11 extracts in ethyl acetate had 
much stronger activity against B. subtilis (1.30 cm) than against PLR-2 (0.73 cm); however, 
the 17SE-11 extract in methanol had no activity against B. subtilis. Both extracts from 17SM-
6, 17SM-14, and 17SM-15 had minimal activity against the two strains of gram-positive 
bacteria. Since the 17SE-10 extract in ethyl acetate had the strongest antibacterial activity 
against both strains of gram-positive bacteria, this strain was prioritized for further study. 
 
Activity Assessment of 17SE-10 
 Multiple “resident-intruder” assays were conducted to assess the activity of 17SE-10 
against other types of Pseudonocardia. Assays were conducted with 17SE-10 as the resident 
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and each 17SE-3 and 17SE-9 as intruders. These strains were selected because both are 
Pseudonocardia collected from T. septentrionalis ants from different colonies. 17SE-10 was 
also assayed against PLR-2 as a positive control. 
 
FIG 4. Resident-intruder assays with17SE-10 as the resident and 17SE-3 (a), 17SE-9 (b), and PLR-2 
(c) as the intruders. Fig 4d shows the growth of 17SE-10 in the absence of any intruders, and Fig 4e 
shows the growth of PLR-2 in the absence of any residents. 
 
 Based on preliminary resident-intruder data (n = 1 for each), 17SE-10 had potent 
activity against all strains tested (Figure 4). The activity against 17SE-9 (zone of inhibition = 
1.85 cm) was stronger than that against PLR-2 (1.00 cm) and 17SE-3 (1.50 cm). Activity 
against 17SE-3 was also stronger than that against PLR-2. This demonstrates that 17SE-10 is 
active against many types of Pseudonocardia bacteria. 
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Activity-Guided Fractionation 
 Since 17SE-10 demonstrated antibiotic abilities against multiple strains of gram-
positive bacteria, the active compound was extracted from 17SE-10 and purified through 
activity-guided fractionation. To begin, a concentrated extract of 17SE-10 was prepared in 
ethyl acetate. This extract was then fractionated through reverse-phase column 
chromatography, using acetonitrile + 0.1% formic acid in varying concentrations as the 
mobile phase. Activity of these fractions was tested against PLR-2 in a spot-on-lawn assay. 
Activity was strongest in fractions 6 (1.75 cm), 7 (2.00 cm), and 8 (1.80 cm), indicating a 
high concentration of antibiotic in these fractions (Figure 5). These fractions eluted at 60-
80% acetonitrile + 0.1% formic acid.  
 
FIG 5. Spot-on-lawn assay results of fractions collected from ethyl acetate extract of 17SE-10. Ten 
fractions were collected through reverse-phase column chromatography with a C-18 column, using 
acetonitrile with 0.1% formic acid in varying concentrations as the mobile phase. Fractions were 
evaporated and rehydrated in methanol. Fractions were tested for activity against PLR-2, a strain of 
Pseudonocardia. Activity of fractions was compared against the crude, unfractionated 17SE-10 ethyl 
acetate extract as well as pure methanol (neg. control). The diameter of each circular zone was 
measured and recorded. 
 
 
 Because there was high activity in the sixth fraction to elute from the column, fraction 
6 was further fractionated through reverse-phase HPLC. Twenty fractions were collected 
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using acetonitrile + 0.1% formic acid in varying concentrations as the mobile phase. 
Fractions were analyzed for absorbance at 300 nm using UV/Vis spectroscopy. Activity of 
these fractions was also tested against PLR-2 in a spot-on-lawn assay. Notable peaks of high-
intensity absorbance eluted in fractions 2 and 3, fraction 5, and fractions 14 and 15 (Figure 
6a). Only fractions 14 and 15 had strong antibiotic activity against PLR-2 (Figure 6b). This 
data indicates that the target antibiotic is likely concentrated in fractions 14 and 15, and that 
the compound absorbs UV light at 300 nm. The lack of other UV-absorbance peaks in 
fractions 14 and 15 suggest that these fractions are relatively purified. 
 
 
FIG 6A. UV chromatogram (λ = 300 nm) for the fractionation of F6 from SepPak chromatography 
using reverse-phase HPLC. F6 was separated into 20 different fractions using acetonitrile with 0.1% 
formic acid in varying concentrations (30% to 100% over 20 minutes, flow rate = 2.500 mL/min) as 
the mobile phase. Bars represent collected fractions. Active fractions 14 and 15 are boxed in red.  
FIG 6B. Spot-on-lawn activity assay of fractions from HPLC fractionation. Fractions were evaporated 
and rehydrated in methanol. Activity of fractions was compared against the unfractionated F6 fraction 
(pos. control) and pure methanol (neg. control). 
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High-Resolution Mass Spectrometry and Preliminary Compound Identification 
Fraction 14 from the HPLC fractionation was analyzed through HR-LCMS coupled 
with UV/Vis spectroscopy. Compounds with high-intensity absorbance at 325 nm eluted at 
4.69 minutes and high total ion counts were present in both positive and negative modes at a 
retention time of 4.9 minutes.  
In negative-ion mode, strong-intensity peaks were present at m/z values of 1307.2408 
and 653.1171 (Figure 7a). Of these, m/z = 1307.2408 likely represents the [M-H+]- peak. In 
positive-ion mode, strong peaks were present at m/z values of 1309.2550, 1291.2444, 
653.3744, and 646.1260 (Figure 7a). Of these, m/z = 1309.2550 likely represents the 
[M+H+]+ peak. Based on the observed masses of positive and negative ions, the exact mass 
of the compound was calculated as 1308.2479 ± 0.0002 Da. 
This exact mass was searched for in the Dictionary of Natural Products, and matched 
only one compound, antibiotic GE37468A.35 This antibiotic was discovered as a natural 
product made by Streptomyces sp. from soil in Italy.36 The exact mass of GE37468A is 
1308.2493 Da, which closely matches the exact mass determined for the antibiotic from 
17SE-10. Based on previous literature characterizing GE37468A, this antibiotic shares a 
similar mass spectrometry pattern to the active compound of 17SE-10, with the peaks of 
strongest intensity occurring around the m/z value of 1291. For these reasons, the active 
compound from 17SE-10 was characterized as antibiotic GE37468A based on initial 
assessment.  
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FIG 7. High-resolution LCMS spectra of F6-14 in each negative ion (A) and positive ion (B) modes. 
Spectra were captured at a retention time of approximately 4.9 minutes. From this data, the exact 
mass of the active compound was calculated as 1308.2479 Da. 
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Comparative Metabolomics of Streptomyces ATCC 55365 and Pseudonocardia 17SE-10 
Antibiotic GE37468A was first characterized and studied as a natural product 
obtained from Streptomyces sp. ATCC 55365. To confirm the characterization of the target 
antibiotic as GE37468A, purified active antibiotics from each 17SE-10 and Streptomyces sp. 
ATCC 55365 were analyzed through high-resolution liquid chromatography and mass 
spectrometry (HR-LCMS/MS). UV/Vis chromatograms at 305 nm and the fragmented and 
unfragmented ions from mass spectrometric analysis were compared between the two 
compounds. For both active fractions, a compound eluted off of the column with high UV 
absorbance at a retention time of 4.6 minutes (Figure S1). Both mass spectra shared identical 
ions at very similar relative ion counts (Figure 8). The m/z = 1309.26 ion for each strain was 
fragmented (collision energy = 28-33 eV), and the ion fragments of each strain all matched in 
m/z values with similar relative ion counts. Resulting ions are all likely from the 
fragmentation of antibiotic GE37468A, as labeled on the figure (Figure 9). Collectively, this 
data strongly suggests that the active compounds of Streptomyces sp. and 17SE-10 are the 
same molecule, which is antibiotic GE37468A. 
	 	
FIG 8. Overlain mass spectrums of 17SE-10 and Streptomyces sp. for compounds that eluted at a 
retention time of 4.6 minutes.  
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B 
 
FIG 9A. MS/MS spectrum of fragmented Streptomyces sp. ion at m/z = 1309.26. The positive ion was 
eluted after 4.639 minutes and was fragmented at the collision energy of 28-33 eV.  
FIG 9B. MS/MS spectrum of fragmented Streptomyces sp. ion at m/z = 1309.26. The positive ion was 
eluted after 4.647 minutes and was fragmented at the collision energy of 28-33 eV. 
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DISCUSSION 
 Data from this study indicates that the tested Pseudonocardia strain associated with 
Trachymyrmex septentrionalis produces antibiotic GE37468A. No prior studies have 
demonstrated the production of this compound by actinobacteria associated with 
Trachymyrmex ants. In fact, this compound has only previously been studied from 
Streptomyces sp. ATCC 55365 in Gerenzano, Italy.36 17SE-10 Pseudonocardia thus serves 
as a novel source for a well-studied compound. This compound has never before been 
identified as part of a defensive symbiosis, and has never been found in the western 
hemisphere. This evidence suggests that the biosynthetic gene cluster for antibiotic 
GE37468A may have somehow migrated from Italy to the United States, and may have been 
incorporated by Pseudonocardia specifically for use in this defensive symbiosis. This novel 
source for the antibiotic therefore poses new questions related to chemical ecology and 
evolution, and further studies will be required to determine how the Trachymyrmex-
associated Pseudonocardia came to acquire and produce this chemical. 
 Since its discovery in 1996, many researchers have studied antibiotic GE37468A to 
clarify its structure and mechanism of activity. The antibiotic belongs to the family of 
ribosomally encoded post-translationally modified peptides (RiPP) and prohibits bacterial 
growth by inhibiting the transcriptional elongation factor (EF-Tu), thus preventing protein 
synthesis.37 The molecule consists of a large macrocycle with ten modified amino acids, as 
well as a four-residue tail of dehydrated amino acids (Figure 10).36  
 Antibiotic GE37468A is considered a thiazolyl peptide, or a thiopeptide. Many 
thiopeptides have been extensively studied due to their potent inhibitory effects on the 
protein synthesis of a broad range of gram-positive bacteria and malarial parasites.38 In 
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particular, thiopeptides have demonstrated antibiotic activity against common human 
pathogens that are prone to antibiotic resistance, including Staphylococcus aureus, 
Enterococcus faecalis, Corynebacterium aurimucosum, Streptococcus mutans, and 
Streptococcus sobrinus.37, 38, 39 Nevertheless, due to poor pharmacokinetics and low water 
solubility, pharmacological uses of thiopeptides have been limited.37 
 Recent studies suggest, however, that bacteria in the human microbiome naturally 
produce thiopeptides. For example, prior studied have demonstrated the presence of the 
biosynthetic gene cluster for lactocillin, a thiopeptide antibiotic, in the genomes of oral and 
vaginal human commensal bacteria. Researchers hypothesized that in this context, lactocillin 
is involved in a defensive symbiosis that selectively protects human hosts from pathogenic 
infections. This conclusion was supported by experiments that demonstrated lactocillin 
activity at low inhibitory concentrations selectively against vaginal and oral pathogens and 
not commensal bacteria.39 
Given that thiopeptides are likely already produced and present in humans, it is 
promising that these antibiotics can be modified for pharmacological usage to treat common 
antibiotic-resistant bacterial infections. To account for the low blood solubility of 
thiopeptides, directed drug delivery mechanisms may be necessary to target the antibiotic 
selectively to pathogens in the body. Some studies have tried to incorporate the biosynthetic 
gene clusters for thiopeptides, including GE37468A, into the genome of existing human 
symbionts as a way to localize production of antibiotics to specific areas in the human 
body.37 
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FIG 10. Structure of antibiotic GE37468A. 
 
 Other approaches may include directed delivery of the antibiotic using nanoparticle 
technology39 or liposomes.41 By exploring alternative drug-delivery mechanisms, 
thiopeptides such as antibiotic GE37468A could prove effective for treating patients with 
otherwise fatal antibiotic-resistant infections. 
 Apart from its potential applications to pharmacology, the discovery of antibiotic 
GE37468A production by ant symbionts poses additional questions to chemical ecology. 
Since this antibiotic has never before been characterized as part of a defensive symbiosis, this 
novel source for the molecule provides the new insight that the chemical may be involved in 
the interspecies interactions of organisms in complex relationships. It is possible that other 
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ant-symbiotic Pseudonocardia could produce this antibiotic as well – especially other 
bacteria associated with Trachymyrmex septentrionalis ants from different ant colonies. 
Further studies are thus required to assess the activity of other Pseudonocardia symbionts of 
Trachymyrmex septentrionalis ants to determine the scope of antiobiotic GE37468A 
production within this system. 
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APPENDIX 
TAB S1. All strains of Pseudonocardia and Escovopsis used. 
Strain Name ID Ant Species Origin 
17SE-3 EV170527-03 T. septentrionalis Long Island, NY 
17SE-9 EV170527-09 T. septentrionalis Long Island, NY 
17SE-10 EV170527-10 T. septentrionalis Long Island, NY 
17SE-11 EV170527-11 T. septentrionalis Long Island, NY 
17SM-1 EV170708-01 T. smithi Las Cruces, NM 
17SM-6 EV170708-06 T. smithi Las Cruces, NM 
17SM-14 EV170708-14 T. smithi Las Cruces, NM 
17SM-15 EV170708-15 T. smithi Las Cruces, NM 
PLR-2 EC080529-05 A. dentigerum Panama 
GA6-1 EV151025-09-1 A. dentigerum Panama 
Escovopsis sp. EV151027-02-2 A. dentigerum Panama 
  
 
FIG S1. UV/Vis chromatogram of purified fractions from Streptomyces ATCC 55365 (red) and 
17SE-10 (blue) obtained during ESI-TOF HR-LCMS/MS analysis of the two compounds. 
Compounds from each strain with a retention time around 4.6 minutes were used for further analysis. 
 
 
 
 
 	
	
